Faustino TorricoJoaquím GascónLourdes OrtizCristina Alonso‐VegaMaría‐Jesús PinazoAlejandro G. SchijmanIgor C. AlmeidaFabiana AlvesNathalie Strub‐WourgaftIsabela Ribeiro2026-03-222026-03-22201810.1016/s1473-3099(17)30538-8https://doi.org/10.1016/s1473-3099(17)30538-8https://andeanlibrary.org/handle/123456789/43080Citaciones: 292enBenznidazolePlaceboMedicineInternal medicineClinical endpointPopulationChagas diseaseAdverse effectRashClinical trialTreatment of adult chronic indeterminate Chagas disease with benznidazole and three E1224 dosing regimens: a proof-of-concept, randomised, placebo-controlled trialarticle